Genelux Corporation

NasdaqCM GNLX

Genelux Corporation Price to Sales Ratio (P/S) on January 14, 2025: 56.08

Genelux Corporation Price to Sales Ratio (P/S) is 56.08 on January 14, 2025, a -72.94% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Genelux Corporation 52-week high Price to Sales Ratio (P/S) is 218.09 on January 17, 2024, which is 288.90% above the current Price to Sales Ratio (P/S).
Genelux Corporation 52-week low Price to Sales Ratio (P/S) is 29.55 on August 05, 2024, which is -47.30% below the current Price to Sales Ratio (P/S).
Genelux Corporation average Price to Sales Ratio (P/S) for the last 52 weeks is 71.23.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: GNLX

Genelux Corporation

CEO	Mr. Thomas Zindrick J.D.
IPO Date	Jan. 26, 2023
Location	United States
Headquarters	2625 Townsgate Road
Employees	24
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Key trends

Past 5 years